icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
SVR12 results from the Phase II, open-label IMPACT study of simeprevir (SMV) in combination with daclatasvir (DCV) and sofosbuvir (SOF) in treatment-na´ve and -experienced patients with chronic HCV genotype 1/4 infection and decompensated liver disease
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco, CA
 
Eric Lawitz,1 Fred Poordad,1 Julio Gutierrez,1 Thomas N Kakuda,2 Gaston Picchio,3
Greet Beets,4 Ann Vandevoorde,4 Pieter Van Remoortere,2 Bert Jacquemyn,4 Gemma Quinn,4 Donghan Luo,2 Sivi Ouwerkerk-Mahadevan,5 Leen Vijgen,4 Veerle Van Eygen,4 Maria Beumont5
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA;
2Janssen Research & Development LLC, Titusville, NJ, USA; 3Janssen Research & Development, San Diego, CA, USA; 4Janssen Infectious Diseases BVBA, Beerse, Belgium;
5Janssen Research & Development, Beerse, Belgium

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif

AASLD15.gif

AASLD16.gif

AASLD17.gif

AASLD18.gif

AASLD19.gif